Remote Patient Management May Reduce All-Cause Mortality in Patients With Heart-Failure and Renal Impairment.
cardiovascular disease
chronic kidney disease
heart failure
randomized controlled trial
remote patient management
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
04
2022
accepted:
14
06
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Remote patient management (RPM) in heart failure (HF) patients has been investigated in several prospective randomized trials. The Telemedical Interventional Management in Heart Failure II (TIM-HF2)-trial showed reduced all-cause mortality and hospitalizations in heart failure (HF) patients using remote patient management (RPM) vs. usual care (UC). We report the trial's results for prespecified eGFR-subgroups. TIM-HF2 was a prospective, randomized, controlled, parallel-group, unmasked (with randomization concealment), multicenter trial. A total of 1,538 patients with stable HF were enrolled in Germany from 2013 to 2017 and randomized to RPM (+UC) or UC. Using CKD-EPI-formula at baseline, prespecified subgroups were defined. In RPM, patients transmitted their vital parameters daily. The telemedical center reviewed and co-operated with the patient's General Practitioner (GP) and cardiologist. In UC, patients were treated by their GPs or cardiologist applying the current guidelines for HF management and treatment. The primary endpoint was the percentage of days lost due to unplanned cardiovascular hospitalizations or death, secondary outcomes included hospitalizations, all-cause, and cardiovascular mortality. Our sub analysis showed no difference between RPM and UC in both eGFR-subgroups for the primary endpoint (<60 ml/min/1.73 m RPM may reduce all-cause mortality and HF hospitalizations in patients with HF and eGFR < 60 ml/min/1.73 m
Sections du résumé
Background
UNASSIGNED
Remote patient management (RPM) in heart failure (HF) patients has been investigated in several prospective randomized trials. The Telemedical Interventional Management in Heart Failure II (TIM-HF2)-trial showed reduced all-cause mortality and hospitalizations in heart failure (HF) patients using remote patient management (RPM) vs. usual care (UC). We report the trial's results for prespecified eGFR-subgroups.
Methods
UNASSIGNED
TIM-HF2 was a prospective, randomized, controlled, parallel-group, unmasked (with randomization concealment), multicenter trial. A total of 1,538 patients with stable HF were enrolled in Germany from 2013 to 2017 and randomized to RPM (+UC) or UC. Using CKD-EPI-formula at baseline, prespecified subgroups were defined. In RPM, patients transmitted their vital parameters daily. The telemedical center reviewed and co-operated with the patient's General Practitioner (GP) and cardiologist. In UC, patients were treated by their GPs or cardiologist applying the current guidelines for HF management and treatment. The primary endpoint was the percentage of days lost due to unplanned cardiovascular hospitalizations or death, secondary outcomes included hospitalizations, all-cause, and cardiovascular mortality.
Results
UNASSIGNED
Our sub analysis showed no difference between RPM and UC in both eGFR-subgroups for the primary endpoint (<60 ml/min/1.73 m
Conclusion
UNASSIGNED
RPM may reduce all-cause mortality and HF hospitalizations in patients with HF and eGFR < 60 ml/min/1.73 m
Identifiants
pubmed: 35899216
doi: 10.3389/fmed.2022.917466
pmc: PMC9309436
doi:
Types de publication
Journal Article
Langues
eng
Pagination
917466Informations de copyright
Copyright © 2022 Naik, Budde, Koehler, Vettorazzi, Pigorsch, Arkossy, Stuard, Duettmann, Koehler and Winkler.
Déclaration de conflit d'intérêts
OA and SS are employed by the company Fresenius Medical Care. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from German Federal Ministry of Education and Research (grant numbers 13KQ0904A, 13KQ0904B, and 13KQ1104A).
Références
Eur Heart J. 2021 Dec 21;42(48):4901
pubmed: 34649282
Int J Mol Sci. 2020 Aug 14;21(16):
pubmed: 32823966
Lancet. 2021 Sep 11;398(10304):991-1001
pubmed: 34461042
Eur J Heart Fail. 2019 Nov;21(11):1445-1458
pubmed: 31129929
Adv Chronic Kidney Dis. 2018 Sep;25(5):382-390
pubmed: 30309455
Clin Res Cardiol. 2015 Aug;104(8):688-96
pubmed: 25777937
Clin J Am Soc Nephrol. 2013 Aug;8(8):1293-303
pubmed: 23660183
Circulation. 2012 Jun 19;125(24):2985-92
pubmed: 22626743
Cochrane Database Syst Rev. 2015 Oct 31;(10):CD007228
pubmed: 26517969
JACC Heart Fail. 2015 Dec;3(12):977-89
pubmed: 26671676
Eur Heart J. 2012 Sep;33(17):2135-42
pubmed: 22888113
Lancet. 2011 Feb 19;377(9766):658-66
pubmed: 21315441
Circulation. 2011 May 3;123(17):1873-80
pubmed: 21444883
Int J Cardiol. 2013 Oct 9;168(4):3691-7
pubmed: 23850320
Lancet. 2018 Sep 22;392(10152):1047-1057
pubmed: 30153985
Am J Cardiol. 2020 Feb 15;125(4):643-650
pubmed: 31843235
Int J Technol Assess Health Care. 2013 Apr;29(2):155-61
pubmed: 23514722
PLoS One. 2016 May 19;11(5):e0155738
pubmed: 27195764
ESC Heart Fail. 2021 Oct;8(5):3613-3620
pubmed: 34182596
Clin Res Cardiol. 2017 Nov;106(11):913-922
pubmed: 28748265
N Engl J Med. 2010 Dec 9;363(24):2301-9
pubmed: 21080835
Int J Cardiol. 2016 Dec 1;224:213-219
pubmed: 27657476
ESC Heart Fail. 2020 Oct;7(5):2516-2526
pubmed: 32558287
Eur J Heart Fail. 2017 Mar;19(3):416-425
pubmed: 27568392
Circ Heart Fail. 2013 May;6(3):473-81
pubmed: 23476054
J Am Soc Nephrol. 2009 Dec;20(12):2625-30
pubmed: 19892934
J Am Coll Cardiol. 2005 May 17;45(10):1654-64
pubmed: 15893183
Lancet. 2016 Jan 30;387(10017):453-61
pubmed: 26560249
Eur J Heart Fail. 2017 Mar;19(3):304-306
pubmed: 28251777
PLoS One. 2019 Jun 19;14(6):e0217696
pubmed: 31216301
Circ Heart Fail. 2012 Jan;5(1):54-62
pubmed: 22167320
J Am Coll Cardiol. 2019 Dec 10;74(23):2893-2904
pubmed: 31806133
JAMA Intern Med. 2016 Mar;176(3):310-8
pubmed: 26857383
Kidney Dis (Basel). 2017 Jan;2(4):151-163
pubmed: 28232932
Curr Med Res Opin. 2016 Oct;32(10):1745-1755
pubmed: 27348501
Eur Heart J. 2016 Nov 01;37(41):3154-3163
pubmed: 26984864
Clin Nephrol. 2018 Sep;90(3):180-184
pubmed: 29701173
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Circulation. 2000 Jul 11;102(2):203-10
pubmed: 10889132
Circulation. 2019 Apr 16;139(16):e840-e878
pubmed: 30852913
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Front Cardiovasc Med. 2021 May 21;8:676658
pubmed: 34095263
Europace. 2015 Aug;17(8):1276-81
pubmed: 25983310
Eur J Heart Fail. 2009 Sep;11(9):847-54
pubmed: 19696057
Eur J Heart Fail. 2018 Oct;20(10):1485-1493
pubmed: 30230666
Sensors (Basel). 2021 May 28;21(11):
pubmed: 34071624
Eur Heart J. 2017 Aug 07;38(30):2352-2360
pubmed: 28575235
Eur J Heart Fail. 2012 Nov;14(11):1208-17
pubmed: 22833614
Lancet. 2014 Aug 16;384(9943):583-590
pubmed: 25131977
Heart Fail Clin. 2019 Oct;15(4):463-476
pubmed: 31472882